Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Dec 16;90(24):1894-900.
doi: 10.1093/jnci/90.24.1894.

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

S A Rosenberg  1 , Y Zhai, J C Yang, D J Schwartzentruber, P Hwu, F M Marincola, S L Topalian, N P Restifo, C A Seipp, J H Einhorn, B Roberts, D E White
Affiliations
Clinical Trial

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

S A Rosenberg et al. J Natl Cancer Inst. .

Abstract

Background: The characterization of the genes encoding melanoma-associated antigens MART-1 or gp100, recognized by T cells, has opened new possibilities for the development of immunization strategies for patients with metastatic melanoma. With the use of recombinant adenoviruses expressing either MART-1 or gp100 to immunize patients with metastatic melanoma, we evaluated the safety, immunologic, and potential therapeutic aspects of these immunizations.

Methods: In phase I studies, 54 patients received escalating doses (between 10(7) and 10(11) plaque-forming units) of recombinant adenovirus encoding either MART-1 or gp100 melanoma antigen administered either alone or followed by the administration of interleukin 2 (IL-2). The immunologic impact of these immunizations on the development of cellular and antibody reactivity was assayed.

Results: Recombinant adenoviruses expressing MART-1 or gp100 were safely administered. One of 16 patients with metastatic melanoma receiving the recombinant adenovirus MART-1 alone experienced a complete response. Other patients achieved objective responses, but they had received IL-2 along with an adenovirus, and their responses could be attributed to the cytokine. Immunologic assays showed no consistent immunization to the MART-1 or gp100 transgenes expressed by the recombinant adenoviruses. High levels of neutralizing antibody were found in the pretreatment sera of the patients.

Conclusions: High doses of recombinant adenoviruses could be safely administered to cancer patients. High levels of neutralizing antibody present in patients' sera prior to treatment may have impaired the ability of these viruses to immunize patients against melanoma antigens.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A 39-year-old female with metastatic melanoma who received four doses of 108 plaque-forming units of adenovirus MART-1 underwent complete regression of biopsy-proven breast and mediastinal metastases. The response is ongoing at 31 months.
Fig. 2
Fig. 2
A) Pretreatment levels of antiadenoviral immunoglobulin G (IgG) (left) or neutralizing (right) antibody in the sera of patients undergoing immunization with recombinant adenovirus encoding MART-1 or gp100. Thirty-four of 45 sera showed an increase in titer of antiadenoviral IgG following administration of adenovirus. Patients receiving interleukin 2 (IL-2) exhibited a higher incidence of increase in IgG than those not receiving IL-2 (P = .004). B) Increase in antiadenoviral IgG and neutralizing antibody in sera of patients receiving recombinant adenovirus encoding MART-1 or gp100.
See this image and copyright information in PMC

References

    1. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst. 1996;88:1635–44. - PubMed
    1. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997;18:175–82. - PubMed
    1. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994;191:6458–62. - PMC - PubMed
    1. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994;91:3515–9. - PMC - PubMed
    1. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180:35–42. - PMC - PubMed

Publication types

MeSH terms